Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611896 | 0.84 | LMNA (0.45) | TSHRSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL7375134 | 0.83 | TSHR (0.71) | TSHRSMN1; SMN2LMNAJAK2JAK3 | |
| SCHEMBL6485391 | 0.79 | HSD17B10 (0.48) | TSHRSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL15897072 | 0.78 | CYP1A2 (0.49) | TSHRSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL6613395 | 0.78 | CYP1A2 (0.49) | TSHRSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL7684125 | 0.77 | LMNA (0.62) | TSHRSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL6804123 | 0.75 | HPGD (0.46) | TSHRSMN1; SMN2ALDH1A1HSD17B10MAPT | |
| SCHEMBL6613616 | 0.75 | POLB (0.48) | TSHRSMN1; SMN2LMNAALDH1A1HSD17B10 | |
| SCHEMBL6615379 | 0.74 | MAPK8 (0.52) | SMN1; SMN2LMNAALDH1A1MAPTKDM4E | |
| SCHEMBL6613947 | 0.74 | ALDH1A1 (0.45) | TSHRSMN1; SMN2LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252157-B1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | disclosed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | disclosed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PDE12, PDE4A, PDE4B | TSHR 3727/4885SMN1; SMN2 4365/4885LMNA 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.